Rituximab
Relapsing-Remitting Multiple Sclerosis
Explore 71 assets in Relapsing-Remitting Multiple Sclerosis →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University Hospital, Montpellier
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07517185CT.gov The HIt HArd and hiT Early in Multiple Sclerosis Trial | — | Not Yet Recruiting | — | — | — |
NCT05482542CT.gov Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis | — | Withdrawn | — | — | — |
NCT04688788CT.gov Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT04121403CT.gov Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | University Hospital, Montpellier | P3 | BB · 64 |
| Natalizumab | Biogen | P4 | BBB |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Phytonadione, (E)-(±)- | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →